Tasigna (nilotinib) — United Healthcare

Initial criteria

• Diagnosis of metastatic or unresectable melanoma cutaneous tumors with activating mutations of KIT
• AND
• Used as second-line or subsequent therapy for disease progression, intolerance, and/or projected risk of progression with BRAF-targeted therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Tasigna therapy

Approval duration

12 months